Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 1st GBHI-Conference – Conference Report now available 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Eye disease Standard operating procedure Slit lamp microscopy Bioequivalence CRA Metered dose inhaler SOP based OTC CDASH Healthy subjects Asthma Non interventional Dose linearity Gynaecological trials Contraception Pulse oximetry plethysmography Investigators brochure Statistical Analysis Plan SDV Clinical development program Ophthalmologist Phase III Product development US FDA Edema Biopharmaceutical Children Glaucoma Safety Phase I Ocular tolerability Network GCP training PASS Elpro CDSIC Phase IIa trials GLP Female adolescents Pharmacodynamic studies Clinical Monitoring Data Validation Plan DUS MMM Postmenopausal women Quality Assurance Life cycle management IB FIM Auditing Creativity Highly variable drugs Centralised procedure US CFR 21 Part 11 Charcoal Xerostomia Pituitary Clinical trials Protocol Consultancy Standardisation Subcontractor qualification Clinical study Cough MDI Scientific advice Training Biosimilars Clinical pharmacology unit Feasibility Drug Food Interaction Legal Information Pharmacokintetics Pharmacokinetics Paediatricians Inhalatives Hypothalamic Anaesthesiologist Oncology Patient recruitment Sore throat EMA Uveitis Patients Post authorisation Good Clinical Practice Lung CDISC CRF GCP Patch adhesion PAES Hormone replacement therapy Phase IV Audit Design development Authorities Transdermal therapeutic system Database NIS Allergy Bioavailability Central surveillance system Source Data Verification HPA axis DPI DFI AGAH Copyright Informed Consent Procedure IEC Early phase Expert Axis TTS Ophthalmological trials Dermal irritation Monitoring Phase I Unit Scientific expertise Phase IIb trials Biopharmaceutics WinNonlin CRO Thuringia Quality Management System ANVISA Endpoint SocraTec C&S Pharmacology Rhine Main area Drug Drug Interaction Statistical services Recruitment rates Cardiovascular surveillance Local tolerability SAS ICF Common cold Protocol development Competence Pragmatism Biometrics Sequential designs IVIVC First in human Sample size estimation Efficacy Project Management ADAM Intensive assessment station Immunogenicity Degeneration Quality Sensitisation trials DDI Oncological patients Oncologic network CDM COPD Absorption Statistical programming Steady state Inspection Spacious archive HRT HTA Dry powder inhaler Experience In vitro in vivo correlation Ovulation inhibition Legal representative Adrenocortical MCID Referral system Data management IMPD Phase II Pilot study FDA Patch Ophthalmology Dry eye Absorption windows Data Management Plan Macular  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page